Literature DB >> 22922342

Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent.

Dong-Lu Bai1, Wei-Zhou Chen, Yun-Xin Bo, Yue-Li Dong, Ai-Li Kang, Wei-Kang Sun, Wei Wang, Zhong-Liang Hu, Yi-Ping Wang.   

Abstract

AIM: To investigate the anti-arrhythmic effects of sulfamide analogues of changrolin and to characterize the sulfate of compound 6f (sulcardine sulfate, Sul) as a novel anti-arrhythmic agent.
METHODS: The anti-arrhythmic effects of compounds were studied against aconitine-induced arrhythmias in rats and ouabain-induced arrhythmias in guinea pigs. The effects of Sul on transmembrane action potentials were investigated in isolated rabbit sinoatrial nodes and guinea-pig papillary muscles using intracellular recording. With a whole-cell recording technique, the effects of Sul on sodium current, calcium current, and potassium currents were examined in isolated single guinea-pig ventricular myocytes.
RESULTS: In aconitine-induced arrhythmias of rats, sulfamide analogues of changrolin (4, 5, and 6a-6p) exhibited various anti-arrhythmic activities. The sulfate of compound 6f (Sul) increased the amount of aconitine required to induce arrhythmias in each treated animal. The ED₅₀ value of Sul in rats was 196 mg/kg. In ouabain-induced arrhythmias of guinea pigs, 25, 50, and 100 mg/kg doses of Sul increased the dose of ouabain required to induce VP, VT, and VF in a dose-dependent manner. In papillary preparations, Sul produced a concentration-dependent decrease in APA and V(max), prolonged APD(90) and ERP, whereas RP was unaffected. In the spontaneously beating sinus nodes, Sul reduced APA and V(max) in a concentration-dependent manner. The whole-cell recording studies revealed that Sul produced a reversible reduction in I(Na) (IC₅₀=26.9 μmol/L) and I(Ca,L)(IC₅₀=69.2 μmol/L), whereas the inward rectifier (I(K1)) and the delayed rectifier potassium currents (I(K)) were unaffected.
CONCLUSION: As a multi-ion channel blocker, Sul may have potent efficacy in anti-atrial and ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922342      PMCID: PMC4003109          DOI: 10.1038/aps.2012.119

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  16 in total

1.  Selective modulation of L-type calcium current by magnesium lithospermate B in guinea-pig ventricular myocytes.

Authors:  Wei Wang; Guo-Yuan Hu; Yi-Ping Wang
Journal:  Life Sci       Date:  2005-12-27       Impact factor: 5.037

2.  [Studies on drugs for coronary diseases. III. Synthesis of some Mannich bases of substituted aminophenols].

Authors:  A L Kang; C J Sun
Journal:  Yao Xue Xue Bao       Date:  1986-12

3.  [Anti-arrhythmia effects of guan-fu base A].

Authors:  W Z Chen; Y L Dong; Y F Zhang; G S Ding
Journal:  Zhongguo Yao Li Xue Bao       Date:  1983-12

4.  Rate-dependent depression of maximal rate of depolarization in guinea pig papillary muscle action potentials by changrolin.

Authors:  Y Kuang; T P Liu
Journal:  Zhongguo Yao Li Xue Bao       Date:  1990-05

Review 5.  Innovative approaches to anti-arrhythmic drug therapy.

Authors:  Stanley Nattel; Leif Carlsson
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

6.  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.

Authors:  D M Stout; W L Matier; C Barcelon-Yang; R D Reynolds; B S Brown
Journal:  J Med Chem       Date:  1984-10       Impact factor: 7.446

7.  Mono- and bis(aminomethyl)phenylacetic acid esters as short-acting antiarrhythmic agents. 2.

Authors:  R J Chorvat; L A Black; V V Ranade; C Barcelon-Yang; D M Stout; B S Brown; H F Stampfli; C Y Quon
Journal:  J Med Chem       Date:  1993-08-20       Impact factor: 7.446

8.  [Effects of guan-fu base a on experimental cardiac arrhythmias and myocardial contractility].

Authors:  Y L Dong; W Z Chen
Journal:  Yao Xue Xue Bao       Date:  1995

9.  Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. 1.

Authors:  D M Stout; L A Black; C Barcelon-Yang; W L Matier; B S Brown; C Y Quon; H F Stampfli
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

10.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more
  5 in total

1.  Celebrating the 80th anniversary of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM).

Authors:  Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2012-09       Impact factor: 6.150

2.  Oral Bioavailability and Mass Balance Studies of a Novel Anti-arrhythmic Agent Sulcardine Sulfate in Sprague-Dawley Rats and Beagle Dogs.

Authors:  You-Li Lu; Shui-Jun Li; Gang-Yi Liu; Xiao-Chuan Li; Ding Yang; Jing-Ying Jia; Meng-Qi Zhang; Hong-Chao Zheng; Chen Yu; Fu Zhu; Yi-Ping Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

3.  Barbaloin inhibits ventricular arrhythmias in rabbits by modulating voltage-gated ion channels.

Authors:  Zhen-Zhen Cao; You-Jia Tian; Jie Hao; Pei-Hua Zhang; Zhi-Pei Liu; Wan-Zhen Jiang; Meng-Liu Zeng; Pei-Pei Zhang; Ji-Hua Ma
Journal:  Acta Pharmacol Sin       Date:  2017-10-26       Impact factor: 6.150

4.  Multiple Dose Pharmacokinetics and Safety of Sulcardine Sulfate in Healthy Chinese Male Subjects: An Open-Label Phase I Clinical Study.

Authors:  Wei Wang; Hong-Jie Qian; Liang Xin; Meng-Qi Zhang; Dong-Ying Lu; Jie-Mei Jin; Gang-Yi Liu; Jing-Ying Jia; Hong-Chao Zheng; Chen Yu; Yi-Ping Wang; Fu Zhu; Yun Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.569

5.  Attenuated Structural Transformation of Indaconitine during Sand Frying Process and Anti-Arrhythmic Effects of Its Transformed Products.

Authors:  Yan Wang; Pei Tao; Yu-Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-17       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.